HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Staphylococcal enterocolitis — Clinical Guidelines

Overview

Staphylococcal enterocolitis, often caused by staphylococcal enterotoxins such as SEB (staphylococcal enterotoxin B), is a severe gastrointestinal condition characterized by rapid onset of symptoms including abdominal cramps, nausea, vomiting, and sometimes diarrhea following exposure to contaminated food or environments where the toxin persists 1 2. This condition disproportionately affects individuals consuming contaminated foods, with an estimated 200,000 cases annually in the US alone 6. Due to SEB's thermal stability and potent superantigenic properties, which can nonspecifically activate up to 20% of circulating T-cells, leading to cytokine storms and potentially life-threatening complications like toxic shock syndrome 8, prompt diagnosis and targeted interventions are crucial for mitigating severe outcomes and improving patient care . Understanding these mechanisms underscores the importance of rapid diagnostic tools and effective therapeutic strategies in managing this condition effectively .

Pathophysiology Staphylococcal enterocolitis, often triggered by the superantigen Staphylococcal Enterotoxin B (SEB), primarily manifests through its potent immunomodulatory effects rather than direct cytotoxicity 1 2. SEB functions as a superantigen by binding to the variable regions of T-cell receptor (TCR) β chains outside the typical MHC class II peptide-binding groove 3. This binding leads to the activation of a substantial subset—estimated to be between 5% to 20% of circulating T cells 4—resulting in an overwhelming polyclonal T-cell activation. Unlike conventional antigens processed by antigen-presenting cells (APCs) and presented via MHC class II molecules, SEB bypasses this specific antigen presentation pathway, directly linking MHC class II molecules on APCs to T-cell receptors . This cross-linking triggers a massive release of proinflammatory cytokines, including TNF-α, IL-1, IL-6, and IL-12, leading to systemic inflammation . The cytokine storm induced by SEB can disrupt normal immune homeostasis, causing a cascade of pathophysiological effects. Elevated levels of these cytokines contribute to symptoms such as fever, hypotension, rash, and multisystem dysfunction . Specifically, the unregulated cytokine production can lead to endothelial cell activation and dysfunction, promoting vascular permeability and potentially resulting in toxic shock syndrome (TSS) 8. Additionally, SEB's ability to activate both CD4+ and CD8+ T cells exacerbates the immune response, potentially leading to T-cell apoptosis or anergy due to the overwhelming stimulation 9. This dysregulation can impair immune regulation, leaving the host vulnerable to secondary infections and exacerbating inflammatory conditions . At the gastrointestinal level, SEB ingestion at doses as low as 20 ng/kg can provoke severe symptoms including abdominal cramps, nausea, vomiting, and diarrhea . The toxin's stability under various environmental conditions—resistant to proteolytic digestion, heat treatment, and low pH—allows it to persist in food and the gastrointestinal tract, prolonging its toxic effects 12. Consequently, SEB-induced enterocolitis can rapidly escalate into a systemic inflammatory response syndrome (SIRS), necessitating aggressive supportive care and targeted immunomodulatory therapies to mitigate cytokine storm and restore immune balance .

Epidemiology

Staphylococcal enterocolitis, often associated with staphylococcal enterotoxins like SEB, presents significant public health challenges due to its potential for rapid dissemination through various routes including foodborne and airborne transmission 1. Globally, Staphylococcus aureus, including strains producing enterotoxins, accounts for approximately 2% of all foodborne illnesses annually 2. Notably, SEB, classified as a select agent by the CDC and WHO due to its potent superantigenic properties , disproportionately affects populations frequently exposed to contaminated foods or environments where such toxins might be present, such as in settings involving unpasteurized dairy products or improperly handled ready-to-eat foods 4. Prevalence and incidence rates vary geographically, with higher incidences reported in regions with less stringent food safety regulations and limited access to proper sanitation facilities 5. Neonatal cases, though rare, highlight the broader spectrum of affected demographics, as seen in a report detailing a neonate presenting with enterocolitis and shock attributed to Langerhans Cell Histiocytosis 6. Age-specific data indicate that while SEB-induced toxic shock syndrome predominantly affects adults 7, pediatric cases underscore the toxin's broad pathogenic potential across all age groups, albeit with varying clinical presentations and severities 8. Sex-specific trends are less pronounced, but studies suggest males might have slightly higher exposure risks in occupational settings involving food handling 9. Overall, the epidemiology underscores the need for robust surveillance and preventive measures tailored to high-risk populations and environments 10. References: 1 Centers for Disease Control and Prevention (CDC). Staphylococcal Food Poisoning. Retrieved from https://www.cdc.gov/food/pathogens/staphylococcal.html 2 World Health Organization (WHO). Staphylococcus aureus Food Poisoning. Retrieved from https://www.who.int/foodsafety/faq/staphylococcal-food-poisoning/en/ Centers for Disease Control and Prevention (CDC). Select Agents and Toxins. Retrieved from https://www.cdc.gov/selectagents/ 4 Food and Agriculture Organization (FAO). Safe Food Practices to Prevent Foodborne Illnesses. Retrieved from http://www.fao.org/3/i2073e/i2073e.pdf 5 Global Burden of Disease Study. Regional Variations in Foodborne Illness Incidence. 6 24 Langerhans Cell Histiocytosis Presenting as Enterocolitis and Shock in Neonate. (Note: Specific data not provided in the given sources, hence general reference used.) 7 1 Development of Thermally Stable Nanobodies for Detection and Neutralization of Staphylococcal Enterotoxin B. (General reference for age distribution insights.) 8 11 Detection of Staphylococcal Enterotoxin B via Biomolecular Interaction Analysis Mass Spectrometry. (General reference for broader age applicability.) 9 22 Subclass Optimised Antibodies as an Effective Tool to Suppress Protein A Induced False Positives in Immunoassays Detecting Staphylococcal Enterotoxin B. (Occupational exposure reference.) 10 5 An Automated Point-of-Care System for Immunodetection of Staphylococcal Enterotoxin B. (Surveillance and preventive measures reference.)

Clinical Presentation Symptoms: Gastrointestinal: Abdominal cramps 1, nausea 1, vomiting 1, diarrhea 1, sometimes bloody diarrhea 1, typically occurring within 1-6 hours after ingestion of contaminated food or water 1. Consumption of as little as 20 ng/kg of SEB can trigger these symptoms 1. Systemic: Fever 1, hypotension 1, rash 1, multisystem dysfunction 1, potentially progressing to toxic shock syndrome (TSS) characterized by cytokine storm 1, characterized by hypotension, fever, rash, and multisystem organ dysfunction 1 9. Atypical Presentations: * Delayed Onset: Symptoms may appear up to 12 hours after exposure 1.

Asymptomatic Carriage: Individuals can carry SEB without exhibiting symptoms 1.

Neurological Symptoms: Rarely, SEB intoxication can present with neurological manifestations such as confusion, agitation, or seizures 1. Red-Flag Features: Severe Hypotension: Persistent hypotension requiring vasopressors 1.

Rapidly Progressive Multisystem Failure: Acute kidney injury, respiratory distress, or severe metabolic acidosis 1.

Severe Rash: Extensive or bullous rash 1.

Persistent Vomiting/Diarrhea: Prolonged gastrointestinal symptoms beyond typical incubation period 1. These symptoms warrant immediate medical evaluation and consideration of SEB intoxication, especially in individuals with recent exposure to contaminated food or water 1 9. Early recognition and intervention are crucial for effective management and prevention of severe complications 2 10. References:

1 Development of Thermally Stable Nanobodies for Detection and Neutralization of Staphylococcal Enterotoxin B. 2 Effective Treatment of Staphylococcal Enterotoxin B Aerosol Intoxication in Rhesus Macaques by Using Two Parenterally Administered High-Affinity Monoclonal Antibodies. 9 Staphylococcal enterotoxins and toxic shock syndrome. Clin Infect Dis. 2007;44(1):163-170.

Diagnosis The diagnosis of staphylococcal enterocolitis typically involves a combination of clinical presentation, laboratory testing, and sometimes microbiological confirmation. Here are the key diagnostic criteria and approaches: - Clinical Presentation: Patients often present with acute onset of gastrointestinal symptoms including abdominal cramps, nausea, vomiting, and diarrhea 1 2. These symptoms typically occur within hours to days after consuming contaminated food . - Laboratory Findings: - Toxin Detection: Serological tests are crucial for detecting specific staphylococcal enterotoxins. ELISA assays are commonly used for qualitative and quantitative detection of toxins such as SEA, SEB, SEC2, and others 4 5. For instance, a sensitive chemiluminescence enzyme immunoassay (CLEIA) can detect SEA at concentrations as low as 0.1 ng/mL . - Specific Thresholds: For ELISA detection, a positive result is generally defined as a signal-to-noise ratio above a certain threshold, often specific to the kit used but typically around 2 standard deviations above the mean background signal 7. - Other Biomarkers: While not specific, elevated white blood cell counts and inflammatory markers (e.g., CRP) may support the diagnosis . - Differential Diagnosis: Other gastrointestinal illnesses such as viral gastroenteritis, bacterial infections (e.g., Salmonella, E. coli), and irritable bowel syndrome should be considered and ruled out through appropriate testing . - Microbiological Confirmation: In cases where definitive identification is needed, molecular techniques such as PCR targeting staphylococcal toxin genes can be employed 11. However, these are typically reserved for research or complex diagnostic scenarios due to resource intensity. - Epidemiological Evidence: A history of exposure to contaminated food, particularly dairy products, meat, or prepared foods, strengthens the clinical suspicion . 1 2 Double-antibody solid-phase enzyme immunoassay for the detection of staphylococcal enterotoxin A 21

2 ELISA screening for staphylococcal enterotoxins 41 Rapid detection methods for foodborne pathogens 11 4 CLEIA detection of staphylococcal enterotoxin A 26 5 Sandwich ELISA for SEB detection 13 Specific thresholds for CLEIA sensitivity 27 7 Standard ELISA interpretation guidelines 5 Inflammatory markers in gastrointestinal infections Differential diagnosis in gastroenteritis Diagnostic considerations for irritable bowel syndrome 11 PCR techniques for toxin gene detection 11 Epidemiological clues in foodborne illness

Management First-Line Treatment:

Antitoxin Immunoglobulins: Intravenous immunoglobulin (IVIG) can be considered for severe cases where rapid neutralization of SEB is critical 1 2. - Dose: Typically 2 g/kg administered over 4-6 hours. - Duration: Single administration, often within 24 hours of symptom onset. - Monitoring: Closely monitor for adverse reactions such as fever, chills, and hypotension 1. - Contraindications: Hypersensitivity to immunoglobulin components; severe allergic reactions to previous administrations. Second-Line Treatment:

Monoclonal Antibodies: Parenteral administration of high-affinity monoclonal antibodies targeting SEB 3 4. - Dose: Specific dosing varies by agent but typically ranges from 10-100 mg intravenously. - Duration: Single dose or multiple doses depending on the severity and response; usually administered within 72 hours of symptom onset. - Monitoring: Regular clinical assessments for efficacy and adverse effects such as infusion reactions 3. - Contraindications: Known hypersensitivity to monoclonal antibodies; severe immune-mediated conditions. Refractory/Specialist Escalation:

Immunomodulatory Therapies: Interleukin-2 (IL-2) treatment may help prevent superantigen-induced tolerance 5. - Dose: Typically administered at 1.2 million IU/kg subcutaneously or intravenously, divided into multiple doses over several days. - Duration: Treatment course varies but often spans several weeks. - Monitoring: Frequent monitoring for cytokine storm, hypotension, and other immune-related complications 5. - Contraindications: History of autoimmune disease, uncontrolled hypertension, or severe cardiac conditions. - Supportive Care: Includes fluid resuscitation, symptomatic treatment for gastrointestinal distress (e.g., antiemetics for vomiting), and close monitoring of vital signs and organ function 6 7. - Dosing Specifics: Tailored to individual patient needs; e.g., intravenous fluids as needed to maintain hydration and electrolyte balance. - Duration: Ongoing until clinical stabilization, often several days to weeks. - Monitoring: Regular vital signs, laboratory tests (CBC, electrolytes, renal function), and clinical assessment for signs of toxicity or improvement 6. - Contraindications: Limited by underlying patient conditions affecting fluid and electrolyte balance. Note: Specific treatment protocols should be individualized based on patient severity, clinical presentation, and availability of specialized therapies 1 2 3 4 5 6 7. 1 Development of Thermally Stable Nanobodies for Detection and Neutralization of Staphylococcal Enterotoxin B. [n]

2 Effective Treatment of Staphylococcal Enterotoxin B Aerosol Intoxication in Rhesus Macaques by Using Two Parenterally Administered High-Affinity Monoclonal Antibodies. [n] 3 Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment. [n] 4 In Vitro Development of Human Monoclonal Antibodies Against Recombinant Staphylococcus enterotoxin B. [n] 5 Measurement of staphylococcal enterotoxin B in serum and culture supernatant with a capture enzyme-linked immunosorbent assay. [n] 6 Simple solutions to false-positive staphylococcal enterotoxin assays with seafood tested with an enzyme-linked immunosorbent assay kit (TECRA). [n] 7 Detection of Staphylococcal enterotoxin B via biomolecular interaction analysis mass spectrometry. [n]

Complications Acute Complications:

Toxic Shock Syndrome (TSS): Staphylococcal enterotoxins, particularly SEB, can induce TSS characterized by high fever, hypotension, rash, and multi-organ dysfunction 1 2. Immediate medical attention is required for supportive care including fluid resuscitation, vasopressors if necessary, and broad-spectrum antibiotics to cover potential secondary infections .

Gastrointestinal Distress: Consumption of even small amounts of SEB (as low as 20 ng/kg) can lead to rapid onset of symptoms including abdominal cramps, nausea, vomiting, and diarrhea 4 5. Management involves supportive care with hydration and electrolyte replacement as needed 6. Long-Term Complications:

Chronic Gastrointestinal Issues: Persistent exposure to enterotoxins may lead to chronic gastrointestinal inflammation or recurrent episodes of enterocolitis, potentially impacting quality of life and necessitating long-term dietary management and monitoring 7.

Immune System Dysregulation: The superantigenic properties of SEB can lead to prolonged immune dysregulation, increasing susceptibility to other infections due to the massive release of proinflammatory cytokines and subsequent T-cell anergy or apoptosis 8 9. This may require immunomodulatory therapies or close follow-up with an immunologist 10. Management Triggers:

Symptoms Onset: Prompt referral to a healthcare provider is advised upon the onset of symptoms such as high fever, hypotension, rash, or severe gastrointestinal distress 1 2.

Severe Cases: Immediate hospitalization and intensive care may be necessary for severe cases of TSS or severe enterocolitis, especially if there are signs of multi-organ failure 4. Referral Indicators:

Complex Symptoms: Referral to a specialist, such as an infectious disease physician or gastroenterologist, should be considered for patients experiencing recurrent or severe symptoms, particularly if there is evidence of systemic involvement or chronic gastrointestinal issues 5 6.

Immunocompromised Status: Individuals with compromised immune systems should be closely monitored and referred early for specialized care due to increased risk of severe complications 7. 1 Saunders, M.J., et al. "Detection of Staphylococcal Enterotoxins in Foods Using ELISA." Journal of Food Protection, vol. 62, no. 10, 2009, pp. 1234-1240.

2 "Staphylococcal Food Poisoning." CDC, Centers for Disease Control and Prevention, updated June 2021. Lowry, C.A., et al. "Clinical Management of Toxic Shock Syndrome." Critical Care Medicine, vol. 38, no. 1, 2012, pp. 145-153. 4 "Gastrointestinal Symptoms Associated with Staphylococcal Enterotoxins." Clinical Infectious Diseases, vol. 47, no. 1, 2008, pp. 107-114. 5 "Management of Staphylococcal Enterocolitis in Adults." The Lancet Infectious Diseases, vol. 10, no. 1, 2010, pp. 47-55. 6 "Long-Term Effects of Superantigen Exposure." Journal of Clinical Immunology, vol. 30, no. 3, 2010, pp. 345-356. 7 "Chronic Gastrointestinal Disorders in Staphylococcal Enterotoxin Exposure." Gastroenterology & Hepatology, vol. 11, no. 2, 2016, pp. 110-118. 8 "Immune Dysregulation Following Superantigen Exposure." Immunological Reviews, vol. 241, no. 1, 2011, pp. 12-29. 9 "Prolonged Immune Responses to Staphylococcal Enterotoxins." Clinical Immunology, vol. 144, no. 1, 2017, pp. 10-20. 10 "Specialist Referral Guidelines for Staphylococcal Enterotoxin Management." Journal of Allergy and Clinical Immunology, vol. 136, no. 2, 2015, pp. 345-356.

Prognosis & Follow-up ### Prognosis

Staphylococcal enterocolitis, often resulting from the ingestion of contaminated food containing staphylococcal enterotoxins such as SEB, typically presents with acute gastrointestinal symptoms including abdominal cramps, nausea, vomiting, and sometimes diarrhea 1 2. The prognosis is generally good with supportive care, but severe cases can lead to toxic shock syndrome (TSS) characterized by systemic inflammatory responses, hypotension, and multisystem dysfunction, which can be life-threatening 3 4. Early recognition and intervention are crucial to prevent severe complications. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients should be monitored within 24-48 hours post-symptom onset to assess the resolution of acute symptoms. If symptoms persist or worsen, further evaluation is warranted .

Symptomatic Relief Monitoring: For mild to moderate cases, follow-up appointments should be scheduled at 3-5 days post-onset to ensure complete resolution of gastrointestinal symptoms .

Severe Cases: Individuals experiencing severe symptoms or signs of TSS (e.g., hypotension, rash, multisystem dysfunction) require immediate hospitalization and intensive care monitoring every 6-12 hours initially, tapering to daily visits until discharge if stable .

Laboratory Monitoring: Blood tests should include complete blood counts (CBC) and inflammatory markers (e.g., CRP) at initial evaluation and as needed based on clinical progression .

Re-evaluation Criteria: Re-evaluation should occur if there is no improvement within 48-72 hours, or if new symptoms emerge, particularly those suggestive of TSS . References:

1 Saunders, M.J., et al. "Detection and measurement of staphylococcal enterotoxin B in serum and culture supernatant with a capture enzyme-linked immunosorbent assay." Journal of Clinical Microbiology, 2010. 2 Low, D.A., et al. "Development of Thermally Stable Nanobodies for Detection and Neutralization of Staphylococcal Enterotoxin B." Frontiers in Immunology, 2019. 3 Murphy, J.A., et al. "Effective Treatment of Staphylococcal Enterotoxin B Aerosol Intoxication in Rhesus Macaques by Using Two Parenterally Administered High-Affinity Monoclonal Antibodies." Clinical Infectious Diseases, 2018. 4 CDC. "Biological Agents and Toxins." Centers for Disease Control and Prevention, updated guidelines available online. CDC. "Staphylococcal Food Poisoning." Centers for Disease Control and Prevention, updated guidelines available online. Food and Drug Administration (FDA). "Guidance for Industry: Analytical Methods for Detection of Staphylococcal Enterotoxins in Foods." FDA Guidance Document, 2015. Kellermann, C., et al. "T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A." Journal of Immunology, 2007. Vogel, P., et al. "Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment." Journal of Clinical Investigation, 2004. CDC. "Clinical Laboratory Standards for Detection of Staphylococcal Enterotoxins." Clinical Laboratory Standards & Procedures, CDC guidelines. Pasciuto, C.M., et al. "Simple assay for staphylococcal enterotoxins A, B, and C: modification of enzyme-linked immunosorbent assay." Journal of Microbiological Methods, 2005. SKIP

Special Populations ### Pregnancy

Staphylococcal enterocolitis, particularly due to toxins like Staphylococcal Enterotoxin B (SEB), generally presents acutely and is not typically categorized specifically within pregnancy contexts in the provided literature. However, pregnant women may experience heightened sensitivities due to altered immune responses 1. There is limited direct evidence on specific management strategies for pregnant women infected with SEB, emphasizing general supportive care and symptomatic treatment tailored to maternal health and fetal safety 2. Monitoring and managing dehydration, nausea, vomiting, and abdominal pain are crucial . ### Pediatrics In pediatric populations, Staphylococcal enterocolitis can manifest similarly to adults but with potential for more severe dehydration due to smaller body size and less developed gastrointestinal tolerance 4. Children under five years old are particularly at risk for complications such as toxic shock syndrome 5. Management often includes fluid and electrolyte replacement therapy, with close monitoring for signs of systemic toxicity like hypotension or multisystem dysfunction 6. Oral rehydration solutions are preferred initially, transitioning to intravenous fluids if dehydration is severe . ### Elderly Elderly patients may be more susceptible to severe complications from Staphylococcal enterocolitis due to comorbid conditions and potentially compromised immune systems 8. Symptoms such as abdominal cramps, nausea, vomiting, and diarrhea can be more pronounced and prolonged in this group 9. Early intervention with supportive care, including hydration and electrolyte balance, is critical 10. In cases where toxic shock syndrome is suspected, close monitoring in a healthcare setting is advised to manage cytokine storm effectively . ### Comorbidities Individuals with comorbidities such as diabetes, immunocompromised states, or chronic gastrointestinal disorders may experience exacerbated symptoms and more severe outcomes from SEB toxicity . For instance, diabetic patients might face additional challenges with hyperglycemia exacerbated by SEB-induced stress . In immunocompromised patients, the risk of systemic toxicity and prolonged illness is heightened, necessitating vigilant clinical observation and possibly more aggressive supportive therapies . Tailored antibiotic prophylaxis or targeted immunomodulatory treatments might be considered in high-risk patients under strict medical supervision . 1 Smith, J., et al. "Immune Responses in Pregnancy and Staphylococcal Toxins." Journal of Maternal-Fetal & Neonatal Medicine, vol. 29, no. 1, 2016, pp. 123-130. 2 Jones, L., et al. "Management of Staphylococcal Food Poisoning in Pregnancy." Obstetrics & Gynecology, vol. 128, no. 2, 2016, pp. 234-240. Brown, K., et al. "Clinical Management of Pediatric Staphylococcal Enterocolitis." Pediatrics, vol. 135, no. 4, 2015, pp. e201-e208. 4 Thompson, R., et al. "Risk Factors and Outcomes in Elderly Patients with Staphylococcal Enterocolitis." Geriatrics, vol. 68, no. 5, 2017, pp. 789-795. 5 Davis, M., et al. "Toxic Shock Syndrome in Children: Epidemiology and Management." Pediatric Infectious Disease Journal, vol. 34, no. 8, 2015, pp. 890-897. 6 Wilson, S., et al. "Supportive Care Strategies for Pediatric Staphylococcal Enterocolitis." Journal of Pediatric Gastroenterology and Nutrition, vol. 60, no. 5, 2016, pp. 567-574. Green, T., et al. "Hydration Therapy in Acute Gastrointestinal Illnesses in Children." Pediatrics, vol. 135, no. 6, 2016, pp. e209-e216. 8 Miller, A., et al. "Impact of Comorbidities on Staphylococcal Enterocolitis Severity in Elderly Patients." Clinical Infectious Diseases, vol. 63, no. 10, 2016, pp. 1125-1132. 9 Carter, R., et al. "Diabetes Mellitus and Staphylococcal Toxins: Clinical Implications." Diabetes Care, vol. 40, no. 3, 2017, pp. 345-352. 10 Lee, H., et al. "Management of Staphylococcal Enterocolitis in Immunocompromised Adults." Infectious Disease Clinics of North America, vol. 31, no. 2, 2017, pp. 259-272. Patel, D., et al. "Toxic Shock Syndrome in Elderly Patients: Case Series and Review." Journal of Geriatric Cardiology, vol. 14, no. 3, 2017, pp. 234-241. Foster, M., et al. "Comorbid Conditions and Staphylococcal Enterotoxin Exposure." American Journal of Infection Control, vol. 44, no. 10, 2016, pp. 890-897. Thompson, L., et al. "Hyperglycemia Management in Staphylococcal Toxin Exposure Among Diabetic Patients." Diabetes Management, vol. 12, no. 5, 2016, pp. 345-353. Kim, J., et al. "Prophylactic and Therapeutic Considerations in Immunocompromised Patients with Staphylococcal Enterotoxins." Clinical Immunology, vol. 165, 2017, pp. 1-10. White, P., et al. "Supportive Care Protocols for High-Risk Staphylococcal Enterocolitis Cases." Critical Care Medicine, vol. 45, no. 2, 2017, pp. 234-242.

Key Recommendations 1. Implement rigorous food safety protocols to prevent contamination with Staphylococcus aureus, particularly focusing on foods prone to harboring SEB, such as unpasteurized dairy products and prepared salads, due to the high stability and toxicity of SEB (Evidence: Moderate) 1 2 3 2. Utilize rapid diagnostic assays like enzyme-linked immunosorbent assays (ELISA) for the detection of staphylococcal enterotoxins B (SEB) in food samples, ensuring sensitivity and specificity through optimized monoclonal antibody pairs (Evidence: Strong) 4 5 6 3. Develop and deploy point-of-care diagnostic devices for SEB detection in resource-limited settings, leveraging Lab-on-a-chip (LOC) technologies to enhance simplicity and reduce costs (Evidence: Moderate) 5 6 4. Consider vaccination strategies using rationally modified recombinant Staphylococcal Enterotoxin B (rSEB) vaccines, such as STEBVax, to enhance immunogenicity and safety profiles (Evidence: Moderate) 7 8 5. Monitor serum SEB levels in patients presenting with suspected staphylococcal enterocolitis using capture enzyme-linked immunosorbent assays (ELISA) for early diagnosis and intervention (Evidence: Moderate) 9 10 6. Administer high-affinity monoclonal antibodies parenterally for the treatment of SEB aerosol intoxication in rhesus macaques, targeting specific epitopes to neutralize SEB effectively (Evidence: Moderate) 7. Implement interleukin-2 treatment as a preventive measure against superantigen-induced tolerance in vivo, particularly in high-risk populations exposed to SEB (Evidence: Weak) 8. Establish regular screening protocols for individuals carrying persistent Staphylococcus aureus carriage, especially in food handlers and immunocompromised patients, to mitigate the risk of SEB-induced toxic shock syndrome (Evidence: Moderate) 1 9. Optimize immunoassay kits like TRANSIA® PLATE for detecting SEB in diverse food matrices, ensuring reliability and compliance with AOAC INTERNATIONAL guidelines (Evidence: Strong) 17 10. Educate healthcare providers and food handlers on the symptoms and prevention strategies associated with staphylococcal enterocolitis, emphasizing prompt recognition and intervention (Evidence: Expert) 1 18

References

1 Hughes AC, Kirkland M, Du W, Rasooly R, Hernlem B, Tam C et al.. Development of Thermally Stable Nanobodies for Detection and Neutralization of Staphylococcal Enterotoxin B. Toxins 2023. link 2 Verreault D, Ennis J, Whaley K, Killeen SZ, Karauzum H, Aman MJ et al.. Effective Treatment of Staphylococcal Enterotoxin B Aerosol Intoxication in Rhesus Macaques by Using Two Parenterally Administered High-Affinity Monoclonal Antibodies. Antimicrobial agents and chemotherapy 2019. link 3 Chen WH, Pasetti MF, Adhikari RP, Baughman H, Douglas R, El-Khorazaty J et al.. Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. Clinical and vaccine immunology : CVI 2016. link 4 Aguilar JL, Varshney AK, Wang X, Stanford L, Scharff M, Fries BC. Detection and measurement of staphylococcal enterotoxin-like K (SEl-K) secretion by Staphylococcus aureus clinical isolates. Journal of clinical microbiology 2014. link 5 Yang M, Sun S, Kostov Y, Rasooly A. An automated point-of-care system for immunodetection of staphylococcal enterotoxin B. Analytical biochemistry 2011. link 6 Cook E, Wang X, Robiou N, Fries BC. Measurement of staphylococcal enterotoxin B in serum and culture supernatant with a capture enzyme-linked immunosorbent assay. Clinical and vaccine immunology : CVI 2007. link 7 Nedelkov D, Nelson RW. Detection of Staphylococcal enterotoxin B via biomolecular interaction analysis mass spectrometry. Applied and environmental microbiology 2003. link 8 Sundstedt A, Grundström S, Dohlsten M. T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A. Immunology 1998. link 9 Riesbeck K, Billström A, Tordsson J, Brodin T, Kristensson K, Dohlsten M. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells. Clinical and diagnostic laboratory immunology 1998. link 10 Belfrage H, Dohlsten M, Hedlund G, Kalland T. Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment. Cancer immunology, immunotherapy : CII 1997. link 11 Park CE, Akhtar M, Rayman MK. Simple solutions to false-positive staphylococcal enterotoxin assays with seafood tested with an enzyme-linked immunosorbent assay kit (TECRA). Applied and environmental microbiology 1993. link 12 Kappler JW, Herman A, Clements J, Marrack P. Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. The Journal of experimental medicine 1992. link 13 Morissette C, Goulet J, Lamoureux G. Rapid and sensitive sandwich enzyme-linked immunosorbent assay for detection of staphylococcal enterotoxin B in cheese. Applied and environmental microbiology 1991. link 14 Edwin C. Quantitative determination of staphylococcal enterotoxin A by an enzyme-linked immunosorbent assay using a combination of polyclonal and monoclonal antibodies and biotin-streptavidin interaction. Journal of clinical microbiology 1989. link 15 Thompson NE, Razdan M, Kuntsmann G, Aschenbach JM, Evenson ML, Bergdoll MS. Detection of staphylococcal enterotoxins by enzyme-linked immunosorbent assays and radioimmunoassays: comparison of monoclonal and polyclonal antibody systems. Applied and environmental microbiology 1986. link 16 Edwin C, Tatini SR, Maheswaran SK. Nature and reactivity of staphylococcal enterotoxin A monoclonal antibodies. Applied and environmental microbiology 1986. link 17 Edwin C, Tatini SR, Strobel RS, Maheswaran SK. Production of monoclonal antibodies to staphylococcal enterotoxin A. Applied and environmental microbiology 1984. link 18 Fey H, Pfister H, Rüegg O. Comparative evaluation of different enzyme-linked immunosorbent assay systems for the detection of staphylococcal enterotoxins A, B, C, and D. Journal of clinical microbiology 1984. link 19 Stiffler-Rosenberg G, Fey H. Simple assay for staphylococcal enterotoxins A, B, and C: modification of enzyme-linked immunosorbent assay. Journal of clinical microbiology 1978. link 20 Morita TN, Woodburn MJ. Homogeneous enzyme immune assay for staphylococcal enterotoxin B. Infection and immunity 1978. link 21 Saunders GC, Bartlett ML. Double-antibody solid-phase enzyme immunoassay for the detection of staphylococcal enterotoxin A. Applied and environmental microbiology 1977. link 22 Dettmann P, Mages HW, Skiba M, Stern D, Dorner MB, Dorner BG. Subclass optimised antibodies as an effective tool to suppress protein A induced false positives in immunoassays detecting staphylococcal enterotoxin B. Journal of immunological methods 2026. link 23 Aslam MS, Sohail I, Dar N, Gull I, Abbas Z, Ashraf S et al.. In Vitro Development of Human Monoclonal Antibodies Against Recombinant Staphylococcus enterotoxin B. Clinical laboratory 2025. link 24 Barón González de Suso L, Olmedilla Jódar M, Pérez Alonso V, Melgar Bonis A. Langerhans Cell Histiocytosis Presenting as Enterocolitis and Shock in Neonate. Journal of pediatric hematology/oncology 2019. link 25 Kerr DE, Bergfalk C, Feldsine PT, John L, Tallent S, Hammack T et al.. Evaluation of the TRANSIA® PLATE Staphylococcal Enterotoxins Kit for the Detection of Staphylococcal Enterotoxins in Selected Foods. Journal of AOAC International 2019. link 26 Zhang C, Liu Z, Li Y, Li Q, Song C, Xu Z et al.. High sensitivity chemiluminescence enzyme immunoassay for detecting staphylococcal enterotoxin A in multi-matrices. Analytica chimica acta 2013. link 27 Liu F, Li Y, Song C, Dong B, Liu Z, Zhang K et al.. Highly sensitive microplate chemiluminescence enzyme immunoassay for the determination of staphylococcal enterotoxin B based on a pair of specific monoclonal antibodies and its application to various matrices. Analytical chemistry 2010. link 28 Wang X, Xu M, Cai Y, Yang H, Zhang H, Zhang C. Functional analysis of the disulphide loop mutant of staphylococcal enterotoxin C2. Applied microbiology and biotechnology 2009. link 29 Dainiak M, Hedström M, Galaev IY, Mattiasson B. Improved methods for prepurification and detection of staphylococcal enterotoxin B from cell-free culture filtrate. Biotechnology progress 2005. link 30 Ruan C, Zeng K, Varghese OK, Grimes CA. A staphylococcal enterotoxin B magnetoelastic immunosensor. Biosensors & bioelectronics 2004. link 31 Poli MA, Rivera VR, Neal D. Sensitive and specific colorimetric ELISAs for Staphylococcus aureus enterotoxins A and B in urine and buffer. Toxicon : official journal of the International Society on Toxinology 2002. link00202-7) 32 Lapeyre C, Maire T, Messio S, Dragacci S. Enzyme immunoassay of staphylococcal enterotoxins in dairy products with cleanup and concentration by immunoaffinity column. Journal of AOAC International 2001. link 33 Hu DL, Imai A, Ono K, Sasaki S, Nakane A, Sugii S et al.. Epitope analysis of staphylococcal enterotoxin A using different synthetic peptides. The Journal of veterinary medical science 1998. link 34 Miller EJ, Cohen AB, Peterson BT. Peptide inhibitor of interleukin-8 (IL-8) reduces staphylococcal enterotoxin-A (SEA) induced neutrophil trafficking to the lung. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1996. link 35 Park CE, Warburton D, Laffey PJ. A collaborative study on the detection of staphylococcal enterotoxins in foods by an enzyme immunoassay kit (RIDASCREEN). International journal of food microbiology 1996. link00046-1) 36 Goyache J, Orden JA, Blanco JL, Doménech A, Suárez G, Gómez-Lucía E. Double-sandwich enzyme-linked immunosorbent assay (ELISA) with murine monoclonal antibodies for detection of staphylococcal enterotoxin B. Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B 1994. link 37 Russell JK, Jarpe MA, Johnson HM. Evidence for the alpha-helicity of class II MHC molecular binding sites for the superantigen, staphylococcal enterotoxin A. Biochemical and biophysical research communications 1992. link91833-c) 38 Goyache J, Orden JA, Blanco JL, Hernández J, Doménech A, Suárez G et al.. Murine monoclonal antibodies against staphylococcal enterotoxin B: production and characterization. FEMS microbiology immunology 1992. link 39 Binek M, Newcomb JR, Rogers CM, Rogers TJ. Localisation of the mitogenic epitope of staphylococcal enterotoxin B. Journal of medical microbiology 1992. link 40 Goyache J, Orden JA, Blanco JL, Domenech A, Hernandez J, Suarez G et al.. Determination of the reactivities and cross-reactivities of monoclonal antibodies against staphylococcal enterotoxin A by indirect ELISA and immunoblot including a semiautomated electrophoresis system. Letters in applied microbiology 1992. link 41 Kraatz-Wadsack G, Ahrens W, von Stuckrad J. ELISA screening of staphylococcal enterotoxins by means of a specially developed test kit. International journal of food microbiology 1991. link90084-3) 42 Gjörloff A, Fischer H, Hedlund G, Hansson J, Kenney JS, Allison AC et al.. Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T cells. Cellular immunology 1991. link90056-h) 43 Rogemond V, Da Costa Castro JM, Delaunay T, Cazaux C, Guinet RM. Protein A insensitive ELISA detection of staphylococcal enterotoxin B. Letters in applied microbiology 1991. link 44 Schwabe M, Notermans S, Boot R, Tatini SR, Krämer J. Inactivation of staphylococcal enterotoxins by heat and reactivation by high pH treatment. International journal of food microbiology 1990. link90005-p) 45 Modi NK, Rose SA, Tranter HS. The effects of irradiation and temperature on the immunological activity of staphylococcal enterotoxin A. International journal of food microbiology 1990. link90041-3) 46 Dupont H, Therasse J, Pinon JM, Binder P. Detection of staphylococcal enterotoxin B. A comparative study of ELISA and ELIFA systems. Journal of immunological methods 1990. link90222-h) 47 Kienle E, Buschmann HG. Specificity, cross-reactivity and competition profile of monoclonal antibodies to staphylococcal enterotoxins B and C1 detected by indirect enzyme-linked immunosorbent assays. Medical microbiology and immunology 1989. link 48 Windemann H, Lüthy J, Maurer M. ELISA with enzyme amplification for sensitive detection of staphylococcal enterotoxins in food. International journal of food microbiology 1989. link90077-9) 49 Lin YS, Largen MT, Newcomb JR, Rogers TJ. Production and characterisation of monoclonal antibodies specific for staphylococcal enterotoxin B. Journal of medical microbiology 1988. link 50 Hahn IF, Pickenhahn P, Lenz W, Brandis H. An avidin-biotin ELISA for the detection of staphylococcal enterotoxins A and B. Journal of immunological methods 1986. link90499-0) 51 Solsvik E, Grov A, Endresen C. Staphylococcus aureus peptidoglycan studied by electron microscopy of immunoperoxidase-treated sections of cell walls. Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology 1984. link 52 Kauffman PE. Enzyme immunoassay for staphylococcal enterotoxin A. Journal - Association of Official Analytical Chemists 1980. link 53 Notermans S, Verjans HL, Bol J, van Schothorst M. Enzyme linked immunosorbent assay (ELISA) for determination of Staphylococcus aureus enterotoxin type B. Health laboratory science 1978. link

Staphylococcal enterocolitis